@article{6948e09c-b35f-4924-907a-f9102a56e3a2,
  abstract     = {{Background: Over the past decades, evidence supporting the antidepressant efficacy of the dopamine agonist pramipexole as an augmentation strategy in mood disorders has accumulated. While dopaminergic treatments have been associated with behavioural adverse effects, the relationship between pramipexole treatment and incident substance use disorder in psychiatric populations remains poorly understood.Aims: To examine the association between cumulative pramipexole exposure and incident substance use disorder among individuals with unipolar depression or bipolar disorder.Methods: We utilised data from Swedish national registries to conduct a nationwide cohort study including individuals with unipolar depression or bipolar disorder treated in specialised mental health care (n = 3105) who were prescribed pramipexole. Cumulative pramipexole exposure was modelled longitudinally and analysed as a time-varying variable. The primary outcome was incident substance use disorder identified in specialised healthcare registers. Associations were examined using Cox proportional hazards models, with analyses separated by diagnostic subgroup.}},
  author       = {{Lindström, Sara and Wolfschlag, Mirjam and Håkansson, Anders C and Berge, Jonas}},
  issn         = {{1664-0640}},
  language     = {{eng}},
  month        = {{08}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Psychiatry}},
  title        = {{Pramipexole treatment and substance use disorder risk in unipolar and bipolar depression: a Swedish nationwide register study}},
  url          = {{http://dx.doi.org/10.3389/fpsyt.2026.1919633}},
  doi          = {{10.3389/fpsyt.2026.1919633}},
  volume       = {{17}},
  year         = {{2026}},
}